start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=1
article-no=
start-page=85
end-page=89
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=201902
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy.
en-copyright=
kn-copyright=

en-aut-name=AbeYoshiyuki
en-aut-sei=Abe
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujibayashiKazutoshi
en-aut-sei=Fujibayashi
en-aut-mei=Kazutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NishizakiYuji
en-aut-sei=Nishizaki
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YanagisawaNaotake
en-aut-sei=Yanagisawa
en-aut-mei=Naotake
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NojiriShuko
en-aut-sei=Nojiri
en-aut-mei=Shuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakanoSoichiro
en-aut-sei=Nakano
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TadaKurisu
en-aut-sei=Tada
en-aut-mei=Kurisu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamajiKen
en-aut-sei=Yamaji
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TamuraNaoto
en-aut-sei=Tamura
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=

affil-num=2
en-affil=Medical Technology Innovation Center, Juntendo University
kn-affil=

affil-num=3
en-affil=Medical Technology Innovation Center, Juntendo University
kn-affil=

affil-num=4
en-affil=Medical Technology Innovation Center, Juntendo University
kn-affil=

affil-num=5
en-affil=Clinical Research and Trial Center, Juntendo University Hospital
kn-affil=

affil-num=6
en-affil=Geriatric General Medicine, Juntendo Tokyo Koto Geriatric Medical Center
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
kn-affil=
en-keyword=pneumocystis pneumonia
kn-keyword=pneumocystis pneumonia
en-keyword=prophylaxis
kn-keyword=prophylaxis
en-keyword=systemic rheumatic disease
kn-keyword=systemic rheumatic disease
en-keyword=sulfamethoxazole-trimethoprim
kn-keyword=sulfamethoxazole-trimethoprim
en-keyword=conventional-dose versus half-dose
kn-keyword=conventional-dose versus half-dose
END